SCHEMBL3409770

SCHEMBL3409770

CC(=O)NCC1(N2CCN(C)CC2)CCN(C(=O)CCC2CCCCN2S(=O)(=O)c2cc(C)c(Cl)cc2C)CC1

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
TP53 P04637 1/20 0.39
BDKRB1 P46663 7/20 0.37
HCN4 Q9Y3Q4 1/20 0.36
LMNA P02545 1/20 0.35
HCN1 O60741 1/20 0.35
EPHX2 P34913 1/20 0.34
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405897 0.90 HCN4 (0.41) HCRTR1HCRTR2TP53HCN4LMNA
SCHEMBL4374697 0.89 HCRTR1 (0.40) HCRTR1HCRTR2BDKRB1EPHX2MAPT
SCHEMBL3406273 0.89 HCRTR1 (0.36) HCRTR1HCRTR2BDKRB1EPHX2
SCHEMBL3405986 0.89 MC4R (0.40) TP53HCN4LMNA
SCHEMBL3402481 0.89 TP53 (0.37) HCRTR1HCRTR2TP53HCN4LMNA
SCHEMBL3407032 0.88 HCN4 (0.40) HCRTR1HCRTR2TP53HCN4LMNA
SCHEMBL3409349 0.87 HCN4 (0.37) HCRTR1HCRTR2TP53HCN4LMNA
SCHEMBL3408874 0.86 HCRTR1 (0.38) HCRTR1HCRTR2BDKRB1LMNA
SCHEMBL3407853 0.85 HCRTR1 (0.37) HCRTR1HCRTR2BDKRB1LMNA
SCHEMBL3407195 0.83 HCRTR1 (0.39) HCRTR1HCRTR2BDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541573-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-09-24 US claimed
EP-2254867-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal Gmbh (DE) 2010-12-01 EP claimed
US-20090298812-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-12-03 US claimed
WO-2009109364-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-11 WO claimed
US-8541573-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-09-24 US disclosed
EP-2254867-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal Gmbh (DE) 2010-12-01 EP disclosed
US-20090298812-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-12-03 US disclosed
WO-2009109364-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298812-A1 Substituted Sulfonamide Compounds BDKRB1, BDKRB2, TRPV1 HCRTR1 558/4885HCRTR2 652/4885TP53 4231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.